Alaunos Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Alaunos Therapeutics, Inc. (TCRT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.95 per share for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2025-08-14
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $1.95, a 79.94% decline year-over-year.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $1.25, a 16.67% decline year-over-year.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-09-30 was $2.06, a 96.48% decline year-over-year.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-06-30 was $9.72, a 82.00% decline year-over-year.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $10.84, a 80.57% decline from fiscal 2023.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $55.80, a 383.54% increase from fiscal 2022.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $11.54, a 340.46% increase from fiscal 2021.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $2.62, a 21.86% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | $1.95 10-Q · filed 2025-08-14 | $2.16 10-Q · filed 2025-08-14 | ||||||
| 2025-03-31 | $1.25 10-Q · filed 2025-05-15 | |||||||
| 2024-12-31 | $10.84 10-K · filed 2025-03-31 | |||||||
| 2024-09-30 | $2.06 10-Q · filed 2024-11-14 | $10.84 10-Q · filed 2024-11-14 | ||||||
| 2024-06-30 | $9.72 10-Q · filed 2025-08-14 | $11.76 10-Q · filed 2025-08-14 | ||||||
| 2024-03-31 | $1.50 10-Q · filed 2025-05-15 | |||||||
| 2023-12-31 | $55.80 10-K · filed 2025-03-31 | $5.58 10-K · filed 2024-04-01 | ||||||
| 2023-09-30 | $58.50 10-Q · filed 2024-11-14 | $0.39 10-Q · filed 2023-11-14 | $58.50 10-Q · filed 2024-11-14 | $0.39 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $54.00 10-Q · filed 2024-08-14 | $0.36 10-Q · filed 2023-08-14 | $58.50 10-Q · filed 2024-08-14 | $0.39 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | $5.85 10-Q · filed 2024-05-15 | $0.39 10-Q · filed 2023-05-10 | ||||||
| 2022-12-31 | $11.54 10-K · filed 2024-04-01 | $0.77 10-K · filed 2023-03-07 | ||||||
| 2022-09-30 | $1.52 10-Q · filed 2023-11-14 | $1.91 10-Q · filed 2023-11-14 | $0.67 10-Q · filed 2022-11-14 | |||||
| 2022-06-30 | $0.55 10-Q · filed 2023-08-14 | $0.48 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | $0.47 10-Q · filed 2023-05-10 | |||||||
| 2021-12-31 | $2.62 10-K · filed 2023-03-07 | |||||||
| 2021-09-30 | $1.08 10-Q · filed 2022-11-14 | $1.91 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | $2.27 10-Q · filed 2022-08-15 | $2.44 10-Q · filed 2022-08-15 | ||||||
| 2021-03-31 | $2.43 10-Q · filed 2022-05-16 | |||||||
| 2020-12-31 | $2.15 10-K · filed 2022-03-30 | |||||||
| 2020-09-30 | $1.96 10-Q · filed 2021-11-08 | $2.45 10-Q · filed 2021-11-08 | ||||||
| 2020-06-30 | $1.99 10-Q · filed 2021-08-13 | $2.55 10-Q · filed 2021-08-13 | ||||||
| 2020-03-31 | $2.64 10-Q · filed 2021-05-06 | |||||||
| 2019-12-31 | $2.47 10-K · filed 2021-03-01 | |||||||
| 2019-09-30 | $3.05 10-Q · filed 2020-11-05 | $1.90 10-Q · filed 2020-11-05 | ||||||
| 2019-06-30 | $3.13 10-Q · filed 2020-08-06 | $1.80 10-Q · filed 2020-08-06 | ||||||
| 2019-03-31 | $1.62 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $1.64 10-K · filed 2021-03-01 | |||||||
| 2018-09-30 | $2.11 10-Q · filed 2019-11-07 | $2.49 10-Q · filed 2019-11-07 | ||||||
| 2018-06-30 | $3.06 10-Q · filed 2019-08-08 | $3.06 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $3.00 10-Q · filed 2019-05-08 | |||||||
| 2017-12-31 | $3.94 10-K · filed 2020-03-02 | |||||||
| 2017-09-30 | $4.29 10-Q · filed 2018-11-09 | $4.34 10-Q · filed 2018-11-09 | ||||||
| 2017-06-30 | $4.48 10-Q · filed 2018-08-08 | $4.45 10-Q · filed 2018-08-08 | ||||||
| 2017-03-31 | $4.48 10-Q · filed 2018-05-10 | |||||||
| 2016-12-31 | $4.43 10-K · filed 2019-03-05 | |||||||
| 2016-09-30 | $3.71 10-Q · filed 2017-11-06 | $5.36 10-Q · filed 2017-11-06 | ||||||
| 2016-06-30 | $5.91 10-Q · filed 2017-07-31 | $5.62 10-Q · filed 2017-07-31 | ||||||
| 2016-03-31 | $3.88 10-Q · filed 2017-05-01 | |||||||
| 2015-12-31 | $10.47 10-K · filed 2018-03-01 | |||||||
| 2015-09-30 | $8.49 10-Q · filed 2016-11-09 | $8.10 10-Q · filed 2016-11-09 | ||||||
| 2015-06-30 | $6.85 10-Q · filed 2016-08-09 | $6.59 10-Q · filed 2016-08-09 | ||||||
| 2015-03-31 | $6.58 10-Q · filed 2016-05-10 | |||||||
| 2014-12-31 | $3.58 10-K · filed 2017-02-16 | |||||||
| 2014-09-30 | $2.29 10-Q · filed 2015-11-02 | $3.15 10-Q · filed 2015-11-02 | ||||||
| 2014-06-30 | $2.84 10-Q · filed 2015-08-10 | $3.23 10-Q · filed 2015-08-10 | ||||||
| 2014-03-31 | $3.34 10-Q · filed 2015-05-07 | |||||||
| 2013-12-31 | $2.51 10-K · filed 2016-02-24 | |||||||
| 2013-09-30 | $2.47 10-Q · filed 2014-10-30 | $1.94 10-Q · filed 2014-10-30 | ||||||
| 2013-06-30 | $1.77 10-Q · filed 2014-08-07 | $1.89 10-Q · filed 2014-08-07 | ||||||
| 2013-03-31 | $3.32 10-Q · filed 2014-05-08 | |||||||
| 2012-12-31 | $3.06 10-K · filed 2015-02-26 | |||||||
| 2012-09-30 | $3.95 10-Q · filed 2013-10-22 | $3.56 10-Q · filed 2013-10-22 | ||||||
| 2012-06-30 | $3.51 10-Q · filed 2013-08-08 | $3.48 10-Q · filed 2013-08-08 | ||||||
| 2012-03-31 | $3.31 10-Q · filed 2013-05-07 | |||||||
| 2011-12-31 | $4.04 10-K · filed 2014-03-03 | |||||||
| 2011-09-30 | $3.88 10-Q · filed 2012-11-08 | $4.18 10-Q · filed 2012-11-08 | ||||||
| 2011-06-30 | $4.69 10-Q/A · filed 2012-08-28 | $4.33 10-Q/A · filed 2012-08-28 | ||||||
| 2010-12-31 | $3.26 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |